Glucagon-like peptide-1 receptor agonists (GLP1RAs) are a class of antidiabetic agents known to reduce cardiovascular events in patients with type II diabetes mellitus (T2DM), overweight, and obese individuals.1 This evidence concerns the gene GLP1R and type 2 diabetes mellitus.